{
    "nctId": "NCT01259505",
    "briefTitle": "Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer",
    "officialTitle": "Phase I Study of Multiple-Vaccine Therapy Using Epitope Peptides Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "safety (Phase I: toxicities as assessed by NCI CTCAE version3)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced or recurrent breast cancer\n* Resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s)\n* Resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* HLA-A\\*2402\n* Laboratory values as follows\n\n  * 2000/mm3\\<WBC\\<15000/mm3\n  * Platelet count\\>100000/mm3\n  * Bilirubin \\< 3.0mg/dl\n  * Asparate transaminase \\< 150IU/L\n  * Alanine transaminase \\< 150IU/L\n  * Creatinine \\< 3.0mg/dl\n* Able and willing to give valid written informed consent\n\nExclusion Criteria:\n\n* Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)\n* Breastfeeding\n* Active or uncontrolled infection\n* Concurrent treatment with steroids or immunosuppressing agent\n* Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks\n* Decision of unsuitableness by principal investigator or physician-in-charge",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}